ATAdam Telerman

Adam Telerman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adam Telerman has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Robert Amson

    Ecole Normale Supérieure; Cachan, France

    3 shared publications
  • A Lespagnol

    Laboratoire de Biotechnologie et Pharmacologie génétique Appliquée (LBPA), Ecole Normale Supérieure, Cachan, France

    2 shared publications
  • C Beekman

    Laboratoire de Biotechnologie et Pharmacologie génétique Appliquée (LBPA), UMR 8113, École Normale Supérieure, Cachan, France

    2 shared publications
  • D Duflaut

    Laboratoire de Biotechnologie et Pharmacologie génétique Appliquée (LBPA), UMR 8113, École Normale Supérieure, Cachan, France

    2 shared publications
  • G Fiucci

    Laboratoire de Biotechnologie et Pharmacologie génétique Appliquée (LBPA), UMR 8113, École Normale Supérieure, Cachan, France

    2 shared publications
  • Jean-Christophe Marine

    Laboratory for Molecular Cancer Biology, Center for Cancer Biology, VIB, Leuven, Belgium

    2 shared publications

Latest Publications

  • Open Access

    Could TCTP contribute to Armin Braun's paradigm of tumor reversion in plants?

    by Robert Amson, Jacek Z. Kubiak, Marc Van Montagu, Adam Telerman


  • Jean Dausset (1916–2009)

    by Adam Telerman, Robert Amson, Peter Demant, Philippa Marrack

  • The molecular programme of tumour reversion: the steps beyond malignant transformation

    by Adam Telerman, Robert Amson

    How cells become malignant has preoccupied scientists for over a century. However, the converse question is also valid: are tumour cells capable of reverting from their malignant state? Askanazy's studies in 1907 indicated that teratoma cells could differentiate into normal somatic tissues and current evidence indicates that some tumour cells have acquired the molecular circuitry that results in the negation of chromosomal instability, translocations, oncogene activation and loss of tumour suppressor genes. Studying these extremely rare events of tumour reversion and deciphering these pathways, which involve SIAH1, presenilin 1, TSAP6 and translationally controlled tumour protein (TCTP), could lead to new avenues in cancer treatment.


  • Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice

    by A Lespagnol, D Duflaut, C Beekman, L Blanc, G Fiucci, J-C Marine, M Vidal, R Amson, A Telerman

    TSAP6 (tumor suppressor-activated pathway 6), also known as Steap3, is a direct p53 transcriptional target gene. It regulates protein secretion, for example translationally controlled tumor protein (TCTP), which is implicated in tumor reversion. In keeping with the latter, we show herein that TSAP6 is a glycosylated protein present in the trans-Golgi network, endosomal–vesicular compartment and cytoplasmic membrane. To further investigate the physiological function of TSAP6, we have generated TSAP6-deficient mice. These mice exhibit microcytic anemia with abnormal reticulocyte maturation and deficient transferrin receptor downregulation, a process known to be dependent on exosomal secretion. Moreover, we provide direct evidence that exosome production is severely compromised in TSAP6-null cells. Finally, we show that the DNA damage-induced p53-dependent nonclassical exosomal secretory pathway is abrogated in TSAP6-null cells. Given the fact that exosomes are used as cell-free vaccines against cancer and that they could be involved in the biogenesis and spread of human immunodeficiency virus, it is important to understand their regulation. The results presented here provide the first genetic demonstration that exosome formation is a tightly controlled biological process dependent of TSAP6.


  • TCTP protects from apoptotic cell death by antagonizing bax function

    by L Susini, S Besse, D Duflaut, A Lespagnol, C Beekman, G Fiucci, A R Atkinson, D Busso, P Poussin, J-C Marine, et al.

    Translationally controlled tumor protein (TCTP) is a potential target for cancer therapy. It functions as a growth regulating protein implicated in the TSC1–TSC2 –mTOR pathway or a guanine nucleotide dissociation inhibitor for the elongation factors EF1A and EF1Bβ. Accumulating evidence indicates that TCTP also functions as an antiapoptotic protein, through a hitherto unknown mechanism. In keeping with this, we show here that loss of tctp expression in mice leads to increased spontaneous apoptosis during embryogenesis and causes lethality between E6.5 and E9.5. To gain further mechanistic insights into this apoptotic function, we solved and refined the crystal structure of human TCTP at 2.0 Å resolution. We found a structural similarity between the H2–H3 helices of TCTP and the H5–H6 helices of Bax, which have been previously implicated in regulating the mitochondrial membrane permeability during apoptosis. By site-directed mutagenesis we establish the relevance of the H2–H3 helices in TCTP's antiapoptotic function. Finally, we show that TCTP antagonizes apoptosis by inserting into the mitochondrial membrane and inhibiting Bax dimerization. Together, these data therefore further confirm the antiapoptotic role of TCTP in vivo and provide new mechanistic insights into this key function of TCTP.